Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
| Revenue (TTM) | $2.62B |
| Gross Profit (TTM) | $2.61B |
| EBITDA | $1.69B |
| Operating Margin | 81.30% |
| Return on Equity | 12.10% |
| Return on Assets | 5.43% |
| Revenue/Share (TTM) | $5.96 |
| Book Value | $15.34 |
| Price-to-Book | 4.40 |
| Price-to-Sales (TTM) | 14.79 |
| EV/Revenue | 14.2 |
| EV/EBITDA | 23.98 |
| Quarterly Earnings Growth (YoY) | -50.80% |
| Quarterly Revenue Growth (YoY) | 13.30% |
| Shares Outstanding | $445.27M |
| Float | $417.57M |
| % Insiders | 6.49% |
| % Institutions | 88.24% |
Volatility is currently contracting
Royalty Pharma (RPRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Royalty Pharma plc is the global leader in acquiring biopharmaceutical royalties, offering investors exposure to blockbuster therapies and megatrend-driven growth. RPRX focuses on de-risked, post-proof-of-concept assets, delivering attractive risk-adjusted returns with a return on invested capital around 15% and equity returns near 21%. The business model is defensive, uncorrelated with macro trends, and benefits from scale, high operating margins, and expert capital allocation.
Royalty Pharma NASDAQ: RPRX reported third-quarter portfolio receipts of $890 million, up 9% from a year earlier, as growth in its diversified royalty portfolio offset declines in certain products. The company raised its full-year 2026 outlook for the third consecutive quarter, citing continued momentum in recurring royalty receipts.
Royalty Pharma plc (RPRX) Q3 2026 Earnings Call Transcript
Although the revenue and EPS for Royalty Pharma (RPRX) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Royalty Pharma (RPRX) came out with quarterly earnings of $1.21 per share, beating the Zacks Consensus Estimate of $1.18 per share. This compares to earnings of $1.17 per share a year ago.
Portfolio Receipts growth of 9% to $890 million; Royalty Receipts growth of 9% Net cash provided by operating activities of $686 million Raised full year 2026 guidance: Portfolio Receipts expected to be $3,500 million to $3,550 million NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the third quarter of 2026 and raised full year 2026 guidance for Portfolio Receipts. “Royalty Pharma delivered excellent third quarter 2026 results and we again raised our financial guidance,” said Pablo Legorreta, Royalty Pharma's Chief Executive Officer and Chairman of the Board.
Beyond analysts' top-and-bottom-line estimates for Royalty Pharma (RPRX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2026.
Royalty Pharma shares have surged ahead of the biotech funding company's Nov. 4 quarterly earnings release. It's unclear whether the company will knock it out of the park this quarter, as was the case with Q2 2026.
Royalty Pharma buys drug royalties. Buying drug royalties provides pharmaceutical companies with cash up front while giving Royalty Pharma a long-term income stream.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on RPRX and any ticker you trade — then tracks every position and per-strategy win rate.
